Do PORTEC-3 and GOG-258 change your approach to managing patients with high-risk or node positive endometrial cancer?  


Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution